We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
Cap. Flow
+$1.16B
Cap. Flow %
36.62%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$16.4M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$9.99M
3
TSLA icon
Tesla
TSLA
+$7.93M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.52%
2 Healthcare 9.63%
3 Energy 0.42%
4 Industrials 0.14%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
226
PUT
DELISTED
Albireo Pharma Inc
ALBO
$24K ﹤0.01%
6
– –
RXII
227
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$21K ﹤0.01%
+139
New +$21K
CVM icon
228
CEL-SCI Corp
CVM
$26.7M
$8K ﹤0.01%
17
– –
AAPL icon
229
CALL
Apple
AAPL
$4.82T
– –
-1,200
Closed -$3.02M
AAPL icon
230
PUT
Apple
AAPL
$4.82T
– –
-1,200
Closed -$3.02M
ABUS icon
231
CALL
Arbutus Biopharma
ABUS
$1B
– –
-883
Closed -$1.87M
ABUS icon
232
PUT
Arbutus Biopharma
ABUS
$1B
– –
-1,212
Closed -$2.56M
ACHC icon
233
CALL
Acadia Healthcare
ACHC
$2.58B
– –
-28,073
Closed -$69.5M
ACHC icon
234
Acadia Healthcare
ACHC
$2.58B
– –
-663,324
Closed -$16.4M
ACHC icon
235
PUT
Acadia Healthcare
ACHC
$2.58B
– –
-1,022
Closed -$2.53M
ALNY icon
236
PUT
Alnylam Pharmaceuticals
ALNY
$32.3B
– –
-773
Closed -$6.04M
ALTO icon
237
Alto Ingredients
ALTO
$311M
– –
-22,900
Closed -$320K
ALTO icon
238
PUT
Alto Ingredients
ALTO
$311M
– –
-317
Closed -$443K
AMGN icon
239
PUT
Amgen
AMGN
$205B
– –
-549
Closed -$7.71M
ARCT icon
240
CALL
Arcturus Therapeutics
ARCT
$444M
– –
-83
Closed -$900K
ARCT icon
241
PUT
Arcturus Therapeutics
ARCT
$444M
– –
-523
Closed -$5.65M
ARWR icon
242
Arrowhead Research
ARWR
$10.3B
– –
-30,513
Closed -$451K
ARWR icon
243
PUT
Arrowhead Research
ARWR
$10.3B
– –
-1,000
Closed -$1.48M
BCLI
244
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-53,884
Closed -$3.32M
BLUE
245
DELISTED
bluebird bio
BLUE
– –
-1,897
Closed -$1.27M
CGEN icon
246
Compugen
CGEN
$229M
– –
-3,400
Closed -$29K
FOCL
247
CALL
EDAP TMS S.A.
FOCL
$190M
– –
-423
Closed -$55K
FOCL
248
EDAP TMS S.A.
FOCL
$190M
– –
-14,524
Closed -$26K
ENTA icon
249
CALL
Enanta Pharmaceuticals
ENTA
$360M
– –
-130
Closed -$514K
EXAS
250
DELISTED
Exact Sciences
EXAS
– –
-21,952
Closed -$534K
8 9
10
11 12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.